171 related articles for article (PubMed ID: 23701746)
1. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E
Vaccine; 2013 Jun; 31(30):3051-8. PubMed ID: 23701746
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
[TBL] [Abstract][Full Text] [Related]
3. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
4. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.
Autumn Smiley M; Sanford DC; Triplett CA; Callahan D; Frolov V; Look J; Ruiz C; Reece JJ; Miles A; Ruiz E; Ionin B; Shearer JD; Savransky V
Vaccine; 2019 Oct; 37(43):6356-6361. PubMed ID: 31530467
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
Hopkins RJ; Howard C; Hunter-Stitt E; Kaptur PE; Pleune B; Muse D; Sheldon E; Davis M; Strout C; Vert-Wong K
Vaccine; 2014 Apr; 32(19):2217-24. PubMed ID: 24613523
[TBL] [Abstract][Full Text] [Related]
7. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
Savransky V; Shearer JD; Gainey MR; Sanford DC; Sivko GS; Stark GV; Li N; Ionin B; Lacy MJ; Skiadopoulos MH
Vaccine; 2017 Sep; 35(37):4952-4959. PubMed ID: 28774566
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older.
Wolfe DN; Espeland EM; Gao Y; Lu D; Blatner G; Amass K; Horwith G; Tong XM; Hopkins R; David GL; Jepson BM; King JC
Vaccine; 2020 Nov; 38(50):7970-7976. PubMed ID: 33129609
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.
Rao VV; Godin CS; Lacy MJ; Inglefield JR; Park S; Blauth B; Reece JJ; Ionin B; Savransky V
Int J Toxicol; 2021 Oct; 40(5):442-452. PubMed ID: 34281421
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.
Shearer JD; Henning L; Sanford DC; Li N; Skiadopoulos MH; Reece JJ; Ionin B; Savransky V
Vaccine; 2021 Jan; 39(1):1-5. PubMed ID: 33199078
[TBL] [Abstract][Full Text] [Related]
11. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.
Wright JG; Plikaytis BD; Rose CE; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Semenova VA; Li H; Schiffer J; Dababneh H; Martin SK; Martin SW; Marano N; Messonnier NE; Quinn CP
Vaccine; 2014 Feb; 32(8):1019-28. PubMed ID: 24373307
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.
Pondo T; Rose CE; Martin SW; Keitel WA; Keyserling HL; Babcock J; Parker S; Jacobson RM; Poland GA; McNeil MM
Vaccine; 2014 Jun; 32(28):3548-54. PubMed ID: 24768633
[TBL] [Abstract][Full Text] [Related]
13. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.
Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M
Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults.
Schneider JC; Chen HC; Bautista E; Retallack D
Vaccine; 2021 Oct; 39(42):6333-6339. PubMed ID: 34544599
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax.
Henning L; Anderson M; Triplett C; Smith T; Boyce K; Hendey L; Ridenour A; Eng J; Schaeufele D; Wilson E; Sabourin CL; Adams LE; Babas T; Parish L; Wolfe D
Hum Vaccin Immunother; 2023 Dec; 19(3):2290345. PubMed ID: 38115181
[TBL] [Abstract][Full Text] [Related]
17. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.
Marano N; Plikaytis BD; Martin SW; Rose C; Semenova VA; Martin SK; Freeman AE; Li H; Mulligan MJ; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Soroka SD; Fox SP; Stamper JL; McNeil MM; Perkins BA; Messonnier N; Quinn CP;
JAMA; 2008 Oct; 300(13):1532-43. PubMed ID: 18827210
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.
King JC; Gao Y; Quinn CP; Dreier TM; Vianney C; Espeland EM
Vaccine; 2015 May; 33(21):2470-6. PubMed ID: 25850022
[TBL] [Abstract][Full Text] [Related]
19. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study.
Kang CK; Kim NH; Kim CJ; Rhie GE; Jo SK; Ahn M; Kang J; Choe PG; Park WB; Kim NJ; Oh MD
Vaccine; 2019 Jun; 37(29):3820-3824. PubMed ID: 31151800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
